Shares of Tilray Inc (NASDAQ:TLRY) have received an average broker rating score of 2.00 (Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold rating and two have given a strong buy rating to the company. Tilray’s rating score has improved by 14.2% in the last three months as a result of various analysts’ ratings changes.
Brokers have set a 12 month consensus price target of $175.00 for the company and are forecasting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also given Tilray an industry rank of 79 out of 256 based on the ratings given to its competitors.
TLRY has been the topic of a number of analyst reports. Northland Securities lowered Tilray from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 6th. Roth Capital reaffirmed a “neutral” rating on shares of Tilray in a research report on Tuesday, October 2nd. Cowen increased their price target on Tilray from $62.00 to $172.00 and gave the company an “outperform” rating in a research report on Tuesday, October 9th. Benchmark assumed coverage on Tilray in a research report on Tuesday, October 16th. They issued a “buy” rating and a $200.00 price target on the stock. Finally, Zacks Investment Research lowered Tilray from a “hold” rating to a “sell” rating in a research report on Tuesday, October 16th.
TLRY stock traded up $0.10 during mid-day trading on Friday, reaching $70.10. The company had a trading volume of 28,389 shares, compared to its average volume of 1,096,300. The company has a quick ratio of 4.98, a current ratio of 5.43 and a debt-to-equity ratio of 0.05. Tilray has a fifty-two week low of $20.10 and a fifty-two week high of $300.00.
Tilray (NASDAQ:TLRY) last posted its quarterly earnings results on Tuesday, November 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.08). The company had revenue of $10.00 million during the quarter, compared to analyst estimates of $10.25 million. Tilray had a negative net margin of 121.22% and a negative return on equity of 60.74%. The firm’s quarterly revenue was up 85.2% on a year-over-year basis. On average, equities research analysts predict that Tilray will post -0.57 EPS for the current fiscal year.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Story: Trading Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.